Latest & greatest articles for fluconazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluconazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluconazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluconazole

1. Fluconazole

Fluconazole Top results for fluconazole - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for fluconazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

2. Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa

Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa (Flucocrypto) The safety and scientific validity of this study is the responsibility of the study sponsor

2012 Clinical Trials

3. Fluconazole administration for the treatment of ductal yeast enfections: clinical effectiveness and safety

Fluconazole administration for the treatment of ductal yeast enfections: clinical effectiveness and safety Fluconazole administration for the treatment of ductal yeast enfections: clinical effectiveness and safety Fluconazole administration for the treatment of ductal yeast enfections: clinical effectiveness and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation CADTH. Fluconazole administration for the treatment of ductal yeast enfections: clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2013 Authors' conclusions No health technology assessments, systematic reviews, randomized controlled trials, or non-randomized studies were identified regarding the clinical effectiveness or safety of fluconazole for the treatment of ductal

2013 Health Technology Assessment (HTA) Database.

4. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis Full Text available with Trip Pro

Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis Neoh CF, Liew D, Slavin M, Marriott D, Chen SC, Morrissey O, Stewart K, Kong DC Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the cost-effectiveness of anidulafungin versus fluconazole in the treatment of invasive candidiasis. The authors concluded that anidulafungin was cost-effective. The methods were adequate, and they and the results were sufficiently reported. Given the scope

2011 NHS Economic Evaluation Database.

5. Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis. Full Text available with Trip Pro

Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis. To compare the safety and efficacy of fluconazole 150 mg single dose and intra-vaginal clotrimazole 200mg per day for six days in the treatment of the acute episode of vulvovaginal candidiasis (VVC).In a prospective study, 142 patients with acute clinical and mycological confirmed VVC were enrolled and divided randomly in two groups. 70 patients received intra-vaginal tablet (200mg (...) ) daily for seven days, whereas 72 patients received single dose oral fluconazole (150 mg). Second and third visits were done for all patients seven days and one month after treatment and the clinical and mycological outcomes evaluated. The analysis performed using SPSS statistical software (version 15).At the second visit, 61 patients (84.7%) were cured clinically (inflammation and discharge) and 58 patients (80.5%) mycologically in fluconazole group and 60 patients (83.3%) were cured clinically

2011 Journal of infection and public health Controlled trial quality: uncertain

6. Clinical effects of topical antifungal therapy in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial of intranasal fluconazole. Full Text available with Trip Pro

Clinical effects of topical antifungal therapy in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial of intranasal fluconazole. Several studies have been in favor of fungi as a possible pathogenesis of chronic rhinosinusitis (CRS); however, to date, there is no scientific consensus about the use of antifungal agents in disease management. The aim of the present study was to investigate the efficacy of intranasal fluconazole in improving disease symptoms and objective (...) outcomes of patients with CRS. A randomized, double-blind, placebo-controlled study was conducted on 54 patients who were diagnosed with CRS and had not been responsive to routine medical treatments. They were randomly assigned to receive either fluconazole nasal drop 0.2 % or placebo in addition to the standard regimen for a duration of 8 weeks. Patients' outcomes were evaluated according to Sino-Nasal Outcome Test 20 (SNOT-20), endoscopic scores, and Computed Tomography (CT) scores. No statistically

2016 EXCLI journal Controlled trial quality: predicted high

7. Safety of oral fluconazole for vulvovaginal candidiasis in pregnancy

Safety of oral fluconazole for vulvovaginal candidiasis in pregnancy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

8. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. (Abstract)

Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Candida vaginitis is currently treated with a wide range of intravaginal preparations usually prescribed over several days. Fluconazole with its marked activity against Candida species and favorable pharmacokinetics offered a safe, effective, and convenient alternative to topical therapy in a single-dose regimen.We conducted a multicenter, randomized (...) , prospective, single-blinded study of 429 patients with acute Candida vaginitis, comparing the efficacy and safety of a single oral 150 mg dose of fluconazole with 7-day clotrimazole 100 mg vaginal treatment. Posttherapy evaluations and mycologic eradication rates were conducted.No statistically significant differences were seen between fluconazole and clotrimazole in the clinical, mycologic, or therapeutic responses. At the 14-day evaluation clinical cure or improvement was seen in 94% of fluconazole

1995 American journal of obstetrics and gynecology Controlled trial quality: uncertain

9. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Full Text available with Trip Pro

Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. HIV-associated cryptococcal meningitis is associated with an estimated 600 000 deaths worldwide per year. Current standard initial therapy consists of amphotericin B (AmB) plus flucytosine (5-FC), but 5-FC remains largely unavailable in Asia and Africa. Alternative, more (...) widely available, and/or more effective antifungal combination treatment regimens are urgently needed.Eighty HIV-seropositive, antiretroviral naive patients presenting with cryptococcal meningitis were randomized to 4 treatment arms of 2 weeks duration: group 1, AmB (0.7-1 mg/kg) and 5-FC (25 mg/kg 4 times daily); group 2, AmB (0.7-1 mg/kg) and fluconazole (800 mg daily); group 3, AmB (0.7-1 mg/kg) and fluconazole (600 mg twice daily); and group 4, AmB (0.7-1 mg/kg) and voriconazole (300 mg twice

2012 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Controlled trial quality: uncertain

10. The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. Full Text available with Trip Pro

The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. To compare the efficacy and safety of two doses of clotrimazole vaginal tablet 500 mg with two doses of oral fluconazole 150 mg in treating severe vulvovaginal candidiasis (SVVC), 240 consecutive patients with SVVC were studied at the Department of Obstetrics and Gynaecology of Peking University Shenzhen Hospital between June 2014, and September 2015. Patients were randomly (...) assigned in a 1 : 1 ratio to receive treatment with either two doses of clotrimazole vaginal tablet or two doses of oral fluconazole. The clinical cure rates in the clotrimazole group and the fluconazole group at days 7-14 follow-up were 88.7% (102/115) and 89.1% (98/110) respectively; the clinical cure rates at days 30-35 in the two groups were 71.9% (82/114) and 78.0% (85/109) respectively. The mycological cure rates at days 7-14 follow-up in the two groups were 78.3% (90/115) and 73.6% (81/110

2016 Mycoses Controlled trial quality: uncertain

11. Miconazole nitrate vaginal suppository 1,200 mg versus oral fluconazole 150 mg in treating severe vulvovaginal candidiasis. Full Text available with Trip Pro

Miconazole nitrate vaginal suppository 1,200 mg versus oral fluconazole 150 mg in treating severe vulvovaginal candidiasis. Miconazole is a synthetic imidazole antifungal that has a broad spectrum of activity against Candida albicans and non-albicans Candida species. The aim of this study was to evaluate the efficacy and safety of miconazole nitrate vaginal suppository and oral fluconazole in treating severe vulvovaginal candidiasis (SVVC).In this prospective, randomized case control study, 577 (...) cases of consecutive patients with SVVC were studied at the Gynecological Clinic of Peking University Shenzhen Hospital from January 1, 2009 through December 31, 2010. Patients with SVVC were treated with two doses of miconazole nitrate vaginal suppository 1,200 mg or two doses of fluconazole 150 mg. The patients were followed up for 7-14 and 30-35 days following the second dose of therapy.The mycological cure rates of the patients on days 7-14 of follow-up were 75.9% (220/290) and 84.0% (241/287

2015 Gynecologic and obstetric investigation Controlled trial quality: uncertain

12. Cohort study: Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus

Cohort study: Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns

2016 Evidence-Based Nursing

13. Fluconazole as a Safe and Effective Alternative to Ketoconazole in Controlling Hypercortisolism of Recurrent Cushing’s Disease: A Case Report Full Text available with Trip Pro

Fluconazole as a Safe and Effective Alternative to Ketoconazole in Controlling Hypercortisolism of Recurrent Cushing’s Disease: A Case Report Ketoconazole has long been the first-line medical therapy for controlling hypercortisolism secondary to either pituitary or adrenal pathology. However, it is largely unavailable in most countries. As a result, we have turned to fluconazole as a viable alternative in view of its favourable safety profile.A 50-year-old lady developed recurrent Cushing's (...) by intolerable side effects including pruritus and skin exfoliation. In the meantime, she suffered a right hypertensive basal ganglia hemorrhage. Treatment was subsequently switched to cabergoline and the dose titrated to 0.5 mg daily. Fluconazole 400 mg daily was later added to control the persistent disease. Her clinical and biochemical parameters improved markedly three months after the addition of fluconazole. No adverse event was reported. Her disease has remained stable for the last 15 months up until

2018 International journal of endocrinology and metabolism

14. Can oral fluconazole be used with breastfeeding?

Can oral fluconazole be used with breastfeeding? Can oral fluconazole be used with breastfeeding? – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice Menu · · Published 21st February 2017 , updated 28th November 2018 There are very limited data on the excretion of fluconazole in breast milk. Fluconazole, after a 200 mg oral dose, produces levels in breast milk similar to those found in maternal plasma. Fluconazole is recommended for use in the treatment (...) of neonates with fungal infections at a dose starting at 3 mg/kg every 72 hours. The calculated dose of fluconazole ingested by an infant feeding at times of peak milk levels of fluconazole would be approximately 0.6 mg/kg/day, which is 60% of the neonatal dose and 20% of the dose for infants aged one month and over. Fluconazole is often used to treat lactation-associated candidal infections, and has been used to treat serious candidal infections in preterm and full term neonates. There is therefore

2017 Specialist Pharmacy Services

15. Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00841971 Recruitment Status : Completed First Posted : February 12, 2009 Results First Posted

2009 Clinical Trials

16. The Study Of Fluconazole For Vulvovaginal Candidiasis

The Study Of Fluconazole For Vulvovaginal Candidiasis The Study Of Fluconazole For Vulvovaginal Candidiasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Study Of Fluconazole For Vulvovaginal (...) to Brief Summary: As for the indication of vulvovaginal candidiasis, a single oral administration of fluconazole 150 mg has been approved and is recommended by guidelines overseas. However in Japan oral therapy with antifungal triazole such as Fluconazole has not been approved, and topical therapies such as vaginal tablets, pessary and cream are used clinically. The purpose of this trial is to confirm the efficacy and safety of single oral administration of fluconazole 150 mg for the treatment

2013 Clinical Trials

17. Fluconazole Administration for the Treatment of Ductal Yeast Infections: Clinical Effectiveness and Safety

Fluconazole Administration for the Treatment of Ductal Yeast Infections: Clinical Effectiveness and Safety TITLE: Fluconazole Administration for the Treatment of Ductal Yeast Infections: Clinical Effectiveness and Safety DATE: 09 December 2013 RESEARCH QUESTIONS 1. What is the clinical evidence for the effectiveness of six-week fluconazole administration for the treatment of ductal yeast infections in breastfeeding mothers? 2. What is the short- and long-term safety of six-week fluconazole (...) administration for the treatment of ductal yeast infections in breastfeeding mothers? KEY MESSAGE No health technology assessments, systematic reviews, randomized controlled trials, or non- randomized studies were identified regarding the clinical effectiveness or safety of fluconazole for the treatment of ductal yeast infections in breastfeeding mothers. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2013, Issue 11), University of York Centre

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

18. Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double-blind randomized study. (Abstract)

Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double-blind randomized study. To compare the safety and efficacy of fluconazole 150mg single dose and itraconazole 200mg per day for 3 days in the treatment of the acute episode of vulvovaginal candidiasis (VVC).Double-blind randomized study conducted in three University centers. Patients with acute clinically and mycologically confirmed VVC were enrolled.A total of 86 (...) patients were enrolled; of them, 38 fluconazole and 32 itraconazole patients were evaluable. At the Day 7 visit, all but one fluconazole patients were cured or improved with eradication of the baseline pathogen obtained in all but two itraconazole patients. At the Day 21 visit, a 13% relapse rate was observed in both groups with all other patients cured or improved; eradication rates were 76% for fluconazole and 66% for itraconazole. Global symptom scores (GSS) were significantly more severe

2003 European journal of obstetrics, gynecology, and reproductive biology Controlled trial quality: uncertain

19. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis

Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

20. Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness

Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions The efficacy of antifungal agents for the treatment of autism has not been demonstrated in published clinical trials or observational studies

2010 Health Technology Assessment (HTA) Database.